Bacteriophage Therapy Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global bacteriophage therapy market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.

Market Outline: Global Bacteriophage Therapy Market
Bacteriophage therapy or phage therapy is used to treat the pathogenic bacterial infections with viruses. These are more specific than bacteria and do not cause any harm to host organism as well as beneficial bacteria such as gut flora. Bacteriophages are most abundant in biosphere and isolated, concentrated, and applied in specific area to eradicate the bacteria. They cause the bacterium to lyse by disrupting the bacterial metabolism. The major advantages with bacteriophages over the antibiotics include very specific, replicate at the site of infection, less side effects and rapidly select the new phages. Bacteriophages can be administered by oral, rectal, intravenous, intrapleural injections, and local applications.

Free sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/bacteriophage-therapy-market/#ulp-4H8Z4LpNMLEuOnnx

Increase in the incidence of antibiotic resistant bacteria strengthen the use of bacteriophage therapy. Moreover, FDA approval for bacteriophage therapies, stringent regulations for the use of antibiotics, promising pipeline drugs under various stages of clinical trials, rise in funding from the public and private sector for bacteriophage therapy research, and wide range of applications with bacteriophage therapeutics are propel the market over the forecast years.

Moreover, most of the market players and research institutes are focused on the R&D activities to develop newer bacteriophage therapies to treat the chronic infections. For instance,

Free TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/bacteriophage-therapy-market/#ulp-c654SbFYO64MsOhu

• AmpliPHI Bioscieces Corporation developing the bacteriophage therapeutics AB-SA01 and AB-PA01. AB-SA01 is developed for the treatment of multi drug resistant aureus infections and completed the two Phase 1 studies. AB-PA01 developed for the treatment of P. aeruginosainfections and completed the pre-clinical studies

• Technophage received FDA clearance for its Investigational New Drug (IND) application to initiate the human clinical trials for bacteriophage TP-102 used in the treatment of chronic ulcers such as diabetic foot disease

Ask Analyst for Full Information about this report @
https://www.precisionbusinessinsights.com/market-reports/bacteriophage-therapy-market/#ulp-14mlyhjMGhVjZqa3

• In January 2018, Pherecydes Pharma raised US$ 10.3 Mn Series B funding led by GO CAPITAL, ACE Management, and Auriga Partners to enter the clinical trials novel bacteriophages PHOSA for the treatment of Staphylococcus aureus infection and PNEUMOPHAGE for the treatment of Pseudomonas aeruginosa respiratory tract infections.

• In March 2017, Intralytix, Inc. received GRAS recognition from FDA for ShigaShield, a non-chemical antimicrobial preparation to control waterborne/foodborne bacterial pathogen Shigella including three major disease-causing species S, sonnei, S. flexneri, and S. dysenteriae. Moreover, company collaborated with Ferring Pharmaceuticals in bacteriophage-based inflammatory bowel disease (IBD) drug development project


Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/bacteriophage-therapy-market/

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com

This release was published on openPR.